Home > Oncology > ESMO 2020 > Gastrointestinal Cancers > Surveillance after curative treatment for CRC

Surveillance after curative treatment for CRC

Conference
ESMO 2020
Regular CEA (carcinoembryonic antigen) assessment is not needed to detect recurrence of colorectal cancer (CRC) and CT scans should only be performed in cases of suspected recurrence, preliminary results of the phase 3 PRODIGE 13 trial showed [1]. Intensive follow-up of patients after curative surgery for CRC is recommended by various scientific societies. PRODIGE 13 is a prospective, multicentre, controlled trial in which 1,995 patients were double randomised in the follow-up of resected stage II or III CRC with no evidence of residual disease on post-surgical investigation. First randomisation was to intensive radiological monitoring (CT scan every 3 months for 3 years, then biannually for 2 years) versus a standard one (abdominal ultrasound every 3 months for 3 years, then biannually for 2 years and thoracic radiography every 6 month for 5 years). Second randomisation was to CEA assessment (every 3 months for 2 years, then biannually for 3 years) versus...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on